Saturday 17 October 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
In the quarter to April 2026, EPS grew 94.0% and free cash flow was flat, each against the same quarter a year earlier.
3.42
0.35
−9.28%
Follow BCTX
| Older periods | Jul '25 | Oct '25 | Jan '26 | Apr '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(359.23%) | (439.51%) | (177.26%) | (173.55%) | |
| (191.21%) | (244.43%) | (137.98%) | (139.20%) | ||
ROIC |
0.00% | 0.00% | (6,192.94%) | (3,311.00%) | |
Return on Tangible Assets |
(161.97%) | (345.68%) | (101.34%) | (138.48%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(66.58) | (15.35) | (11.05) | (4.33) | |
Free Cash Flow |
(28.17) | (28.92) | (30.97) | (31.41) | |
Capital Expenditures |
— | — | — | (0.58) | |
| Other line items | |||||
Cash ROIC |
(80.03%) | (148.11%) | (51.51%) | (67.96%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | 137.34 | 97.29 | |
Operating CF/Net income |
1.07 | 1.01 | 1.04 | 1.00 | |
Depreciation/Fixed assets |
0.36 | 0.39 | 0.42 | 0.32 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (5.17) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(66.58) | (15.35) | (11.05) | (4.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.08) | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026